| SASSE, Stephanie, Magdalena ALRAM, Horst MÜLLER, Lenka ŠMARDOVÁ, Bernd METZNER, Hartmut DOEHNER, Thomas FISCHER, Dietger W. NIEDERWIESER, Norbert SCHMITZ, Kerstin SCHÄFER-ECKART, John M. M. RAEMAEKERS, Oliver SCHMALZ, Bastian V. TRESCKOW, Andreas ENGERT a Peter BORCHMANN. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leukemia & Lymphoma. Abingdon: Taylor & Francis LTD, 2016, roč. 57, č. 5, s. 1067-1073. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2015.1083561. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1323300,
author = {Sasse, Stephanie and Alram, Magdalena and Müller, Horst and Šmardová, Lenka and Metzner, Bernd and Doehner, Hartmut and Fischer, Thomas and Niederwieser, Dietger W. and Schmitz, Norbert and SchäferandEckart, Kerstin and Raemaekers, John M. M. and Schmalz, Oliver and Tresckow, Bastian V. and Engert, Andreas and Borchmann, Peter},
article_location = {Abingdon},
article_number = {5},
doi = {http://dx.doi.org/10.3109/10428194.2015.1083561},
keywords = {DHAP; dose density; hematotoxicity; outcome; relapsed Hodgkin lymphoma},
language = {eng},
issn = {1042-8194},
journal = {Leukemia & Lymphoma},
title = {Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group},
volume = {57},
year = {2016}
}
TY - JOUR
ID - 1323300
AU - Sasse, Stephanie - Alram, Magdalena - Müller, Horst - Šmardová, Lenka - Metzner, Bernd - Doehner, Hartmut - Fischer, Thomas - Niederwieser, Dietger W. - Schmitz, Norbert - Schäfer-Eckart, Kerstin - Raemaekers, John M. M. - Schmalz, Oliver - Tresckow, Bastian V. - Engert, Andreas - Borchmann, Peter
PY - 2016
TI - Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group
JF - Leukemia & Lymphoma
VL - 57
IS - 5
SP - 1067-1073
EP - 1067-1073
PB - Taylor & Francis LTD
SN - 10428194
KW - DHAP
KW - dose density
KW - hematotoxicity
KW - outcome
KW - relapsed Hodgkin lymphoma
N2 - Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in relapsed HL. In order to assess the prognostic relevance of DHAP dose density, we performed a retrospective multivariate analysis of the HDR2 trial (N=266). In addition to four risk factors (early or multiple relapse, stage IV disease or anemia at relapse, and grade IV hematotoxicity during the first cycle of DHAP) a delayed start of the second cycle of DHAP>day 22 predicted a significantly poorer progression-free survival (PFS, p=0.0356) and overall survival (OS, p=0.0025). In conclusion, our analysis strongly suggests that dose density of DHAP has a relevant impact on the outcome of relapsed HL patients.
ER -
SASSE, Stephanie, Magdalena ALRAM, Horst MÜLLER, Lenka ŠMARDOVÁ, Bernd METZNER, Hartmut DOEHNER, Thomas FISCHER, Dietger W. NIEDERWIESER, Norbert SCHMITZ, Kerstin SCHÄFER-ECKART, John M. M. RAEMAEKERS, Oliver SCHMALZ, Bastian V. TRESCKOW, Andreas ENGERT a Peter BORCHMANN. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. \textit{Leukemia \&{} Lymphoma}. Abingdon: Taylor \&{} Francis LTD, 2016, roč.~57, č.~5, s.~1067-1073. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2015.1083561.
|
